Sirona Capital is a Perth, Australia based funds alternative funds manager. They focus on urban renewal, private real estate and agricultural projects. Sirona Capital is an active manager which controls and operates the assets it develops or owns.
Their investment partners are global institutional investors, family offices and high net worth individuals. Investments tend to be five year average investment term. Sirona Capital has AUD$330 million of committed capital in 9 discrete managed funds.
Investment
Sirona Capital has invested in Antiva Biosciences, Constellation Pharmaceuticals, Arvinas, TCR2, Viela Bio, Hookipa Pharma and Codiak Biosciences. They have exited their investments in Arvinas, Constellation Pharmaceuticals, Viela Bio, TCR2 and Hookipa Pharma.
Their real estate funds are the Kings Square Fund, the Pakenham Street Hotel Fund, the Heirloom Fund, the Margaret River Retail Fund, the Adelaide Street Fund, the Lyall Street Fund and the Northern Gateway Fund.
Timeline
Funded Companies
TCR2 Therapeutics is a biotechnology company developing T cell hematologic cancer immunotherapies.
A biopharmaceutical company dedicated to the development of novel therapeutics in the field of Epigenetics
A pharmaceutical company developing protein degradation drugs to treat cancer and other diseases
People
Christina Hill
Office Manager
Daniel Johnston
Senior Associate
Greg Haskis
CFO
Jeff Holloway
Development Director
Johny Sheldrick
Senior Development Manager
Lauren Cross
Community and Public Relations
Leon Boyatzis
Senior Consultant
Matthew McNeilly
Managing Director
Tim Mackey
Director
Further reading
Auto-extract from URL...
Documentaries, videos and podcasts
Auto-extract from URL...
Companies